Q2-osavuosiraportti
84 päivää sitten‧48 min
Tarjoustasot
First North Denmark
Määrä
Osto
230 288
Myynti
Määrä
764 994
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 394 097 | - | - | ||
| 33 796 | - | - | ||
| 112 991 | - | - | ||
| 472 107 | - | - | ||
| 92 788 | - | - |
Ylin
0,011VWAP
Alin
0,01VaihtoMäärä
0 1 168 779
VWAP
Ylin
0,011Alin
0,01VaihtoMäärä
0 1 168 779
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 168 779 | 1 168 779 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 168 779 | 1 168 779 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 4.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 29.5. | |
| 2024 Q4-osavuosiraportti | 29.4. | |
| Merkintäoikeusanti | 13.3. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenInteresting approach, that we are now shifting from talking about benefits of CST to, huge economic upside for care homes. And interesting event. Without it being said directly, Ayla has most likely been mentioned. https://www.linkedin.com/posts/brain-plus_carehomes-healtheconomics-cognitivestimulationtherapy-activity-7399000114045911040-hvCz?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4 https://www.linkedin.com/posts/brain-plus_cst-brainplus-cst-activity-7398646240667803648-LcM_?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4- 21.11.Tämä julkaisu on poistettu.
·20.11.Now people had mentioned that the possibility of an emission is under discussion. But with the activity currently in the UK, shouldn't FOND support not be under discussion? Or Brain + perhaps takes out a loan? I personally don't believe that Brain will once again raise capital through more shares. But time will tell. 2026 will be an exciting year 🤞
·22.11.@k1982 : "speculations" about an emission have arisen because the formulation regarding breakeven was formulated as " within reach", which is a bit weaker than before....... Yes, it doesn't take much before negativity takes over here 😳- ·20.11.I'm simply sticking my neck out and stating that we have reached the bottom now at one øre ( 0,01 ) UNLESS there is a share issue in 2026 which I will of course participate in - then it is the bottom we see now. After the "dramatic downgrade" yesterday which was actually just a postponement of results and the share price has not fallen on that basis, then for me it is a good time to go in and supplement ( of course it is not a recommendation because we are not allowed to ) Merry Christmas and Happy New Year everyone ☃️🤡
21.11.21.11.Tämä kommentti on poistettu.
·21.11.They have just downgraded. And it's actually the second time in a row they do that, which very strongly emphasizes that one should be careful about believing what they say. Their sales forecasts are clearly based on hot air. Regarding break even, they first said mid 2026, which has now become that “we hope for break even in 2026”. Fine enough, if it holds, but you can't count on that. But even if nothing of what they say holds true, you are one of those who naively and uncritically swallow everything devika says, so just believe it. In the meantime, there are others who doubt that they will reach breakeven…and if they don't, it will be difficult to avoid an emission. - ·20.11.Another positive piece of news for Ayla and b+. Again, major changes are happening in the NHS system, which promotes the implementation pace for Ayla. https://www.linkedin.com/posts/clinical-entrepreneur-programme_we-asked-dr-zubir-ahmed-mp-why-is-new-intellectual-activity-7396942583232372736-kvKf?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4·20.11. · MuokattuThere has recently been a webinar from NHS that dealt with the challenges and barriers innovative digital solutions encounter in connection with implementation in NHS, these NHS is now taking consequence of and changing their IP strategy. Department of Health and Social Care, they say directly in the video. We're updatering our guidelines too reflect the modern world and we are using new blueprints to how you can work with the NHS accelerate your inovesions and get them faster too the patients. They do this in a way that benefits both patients/ NHS/inovators and the socio-economic benefits.. All of which has 100% influence on the future of Ayla. It's okay not to understand how NHS operates, and how different mechanisms affect the b+ situation. But then ask instead of being frustrated that you can't see it. It mentions 4 important things. Inovators. = brain+ Socio-economic benefits. = ROI x130 ~ 200.000 pund profit. Patients. = Nearly 50% improvement with Ayla Fast Implementation.= Greater likelihood of break even. So you can experience the post as you wish, but to claim that it is not relevant and has no justification is incorrect. IP guidance for NHS – webinar for innovators 05. December 2025 • 13.30 - 14.30 Online Details As part of the launch of the new IP guidance, DHSC and NHSE are holding a series of webinars aimed at helping the system gain a deeper understanding of the guidance and its objectives, as well as providing an opportunity for questions and answers. This webinar is tailored for innovators. Target audience: Clinical and non-clinical innovators currently working in NHS, innovators who wish or are interested in getting their innovations into NHS, and patient entrepreneurs Content: An introduction to intellectual property rights as described in the new guidance A review of the guidance: what it looks like, who it applies to, and the principles of good practice What the guidance means for innovators Case studies from innovators sharing real-world examples of navigating IP management within NHS in connection with their innovations. Register Microsoft Privacy Policy. This event is run by Microsoft Teams under the meeting organizer's leadership. The data processing that takes place in connection with this event is subject to the meeting organizer's terms.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
84 päivää sitten‧48 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenInteresting approach, that we are now shifting from talking about benefits of CST to, huge economic upside for care homes. And interesting event. Without it being said directly, Ayla has most likely been mentioned. https://www.linkedin.com/posts/brain-plus_carehomes-healtheconomics-cognitivestimulationtherapy-activity-7399000114045911040-hvCz?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4 https://www.linkedin.com/posts/brain-plus_cst-brainplus-cst-activity-7398646240667803648-LcM_?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4
- 21.11.Tämä julkaisu on poistettu.
- ·20.11.Now people had mentioned that the possibility of an emission is under discussion. But with the activity currently in the UK, shouldn't FOND support not be under discussion? Or Brain + perhaps takes out a loan? I personally don't believe that Brain will once again raise capital through more shares. But time will tell. 2026 will be an exciting year 🤞·22.11.@k1982 : "speculations" about an emission have arisen because the formulation regarding breakeven was formulated as " within reach", which is a bit weaker than before....... Yes, it doesn't take much before negativity takes over here 😳
- ·20.11.I'm simply sticking my neck out and stating that we have reached the bottom now at one øre ( 0,01 ) UNLESS there is a share issue in 2026 which I will of course participate in - then it is the bottom we see now. After the "dramatic downgrade" yesterday which was actually just a postponement of results and the share price has not fallen on that basis, then for me it is a good time to go in and supplement ( of course it is not a recommendation because we are not allowed to ) Merry Christmas and Happy New Year everyone ☃️🤡21.11.21.11.Tämä kommentti on poistettu.·21.11.They have just downgraded. And it's actually the second time in a row they do that, which very strongly emphasizes that one should be careful about believing what they say. Their sales forecasts are clearly based on hot air. Regarding break even, they first said mid 2026, which has now become that “we hope for break even in 2026”. Fine enough, if it holds, but you can't count on that. But even if nothing of what they say holds true, you are one of those who naively and uncritically swallow everything devika says, so just believe it. In the meantime, there are others who doubt that they will reach breakeven…and if they don't, it will be difficult to avoid an emission.
- ·20.11.Another positive piece of news for Ayla and b+. Again, major changes are happening in the NHS system, which promotes the implementation pace for Ayla. https://www.linkedin.com/posts/clinical-entrepreneur-programme_we-asked-dr-zubir-ahmed-mp-why-is-new-intellectual-activity-7396942583232372736-kvKf?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4·20.11. · MuokattuThere has recently been a webinar from NHS that dealt with the challenges and barriers innovative digital solutions encounter in connection with implementation in NHS, these NHS is now taking consequence of and changing their IP strategy. Department of Health and Social Care, they say directly in the video. We're updatering our guidelines too reflect the modern world and we are using new blueprints to how you can work with the NHS accelerate your inovesions and get them faster too the patients. They do this in a way that benefits both patients/ NHS/inovators and the socio-economic benefits.. All of which has 100% influence on the future of Ayla. It's okay not to understand how NHS operates, and how different mechanisms affect the b+ situation. But then ask instead of being frustrated that you can't see it. It mentions 4 important things. Inovators. = brain+ Socio-economic benefits. = ROI x130 ~ 200.000 pund profit. Patients. = Nearly 50% improvement with Ayla Fast Implementation.= Greater likelihood of break even. So you can experience the post as you wish, but to claim that it is not relevant and has no justification is incorrect. IP guidance for NHS – webinar for innovators 05. December 2025 • 13.30 - 14.30 Online Details As part of the launch of the new IP guidance, DHSC and NHSE are holding a series of webinars aimed at helping the system gain a deeper understanding of the guidance and its objectives, as well as providing an opportunity for questions and answers. This webinar is tailored for innovators. Target audience: Clinical and non-clinical innovators currently working in NHS, innovators who wish or are interested in getting their innovations into NHS, and patient entrepreneurs Content: An introduction to intellectual property rights as described in the new guidance A review of the guidance: what it looks like, who it applies to, and the principles of good practice What the guidance means for innovators Case studies from innovators sharing real-world examples of navigating IP management within NHS in connection with their innovations. Register Microsoft Privacy Policy. This event is run by Microsoft Teams under the meeting organizer's leadership. The data processing that takes place in connection with this event is subject to the meeting organizer's terms.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
230 288
Myynti
Määrä
764 994
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 394 097 | - | - | ||
| 33 796 | - | - | ||
| 112 991 | - | - | ||
| 472 107 | - | - | ||
| 92 788 | - | - |
Ylin
0,011VWAP
Alin
0,01VaihtoMäärä
0 1 168 779
VWAP
Ylin
0,011Alin
0,01VaihtoMäärä
0 1 168 779
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 168 779 | 1 168 779 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 168 779 | 1 168 779 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 4.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 29.5. | |
| 2024 Q4-osavuosiraportti | 29.4. | |
| Merkintäoikeusanti | 13.3. |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
84 päivää sitten‧48 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 4.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 29.5. | |
| 2024 Q4-osavuosiraportti | 29.4. | |
| Merkintäoikeusanti | 13.3. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenInteresting approach, that we are now shifting from talking about benefits of CST to, huge economic upside for care homes. And interesting event. Without it being said directly, Ayla has most likely been mentioned. https://www.linkedin.com/posts/brain-plus_carehomes-healtheconomics-cognitivestimulationtherapy-activity-7399000114045911040-hvCz?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4 https://www.linkedin.com/posts/brain-plus_cst-brainplus-cst-activity-7398646240667803648-LcM_?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4
- 21.11.Tämä julkaisu on poistettu.
- ·20.11.Now people had mentioned that the possibility of an emission is under discussion. But with the activity currently in the UK, shouldn't FOND support not be under discussion? Or Brain + perhaps takes out a loan? I personally don't believe that Brain will once again raise capital through more shares. But time will tell. 2026 will be an exciting year 🤞·22.11.@k1982 : "speculations" about an emission have arisen because the formulation regarding breakeven was formulated as " within reach", which is a bit weaker than before....... Yes, it doesn't take much before negativity takes over here 😳
- ·20.11.I'm simply sticking my neck out and stating that we have reached the bottom now at one øre ( 0,01 ) UNLESS there is a share issue in 2026 which I will of course participate in - then it is the bottom we see now. After the "dramatic downgrade" yesterday which was actually just a postponement of results and the share price has not fallen on that basis, then for me it is a good time to go in and supplement ( of course it is not a recommendation because we are not allowed to ) Merry Christmas and Happy New Year everyone ☃️🤡21.11.21.11.Tämä kommentti on poistettu.·21.11.They have just downgraded. And it's actually the second time in a row they do that, which very strongly emphasizes that one should be careful about believing what they say. Their sales forecasts are clearly based on hot air. Regarding break even, they first said mid 2026, which has now become that “we hope for break even in 2026”. Fine enough, if it holds, but you can't count on that. But even if nothing of what they say holds true, you are one of those who naively and uncritically swallow everything devika says, so just believe it. In the meantime, there are others who doubt that they will reach breakeven…and if they don't, it will be difficult to avoid an emission.
- ·20.11.Another positive piece of news for Ayla and b+. Again, major changes are happening in the NHS system, which promotes the implementation pace for Ayla. https://www.linkedin.com/posts/clinical-entrepreneur-programme_we-asked-dr-zubir-ahmed-mp-why-is-new-intellectual-activity-7396942583232372736-kvKf?utm_source=share&utm_medium=member_android&rcm=ACoAAB5yFvMBGDwma3GIsqrlG98N5EDm84BK3K4·20.11. · MuokattuThere has recently been a webinar from NHS that dealt with the challenges and barriers innovative digital solutions encounter in connection with implementation in NHS, these NHS is now taking consequence of and changing their IP strategy. Department of Health and Social Care, they say directly in the video. We're updatering our guidelines too reflect the modern world and we are using new blueprints to how you can work with the NHS accelerate your inovesions and get them faster too the patients. They do this in a way that benefits both patients/ NHS/inovators and the socio-economic benefits.. All of which has 100% influence on the future of Ayla. It's okay not to understand how NHS operates, and how different mechanisms affect the b+ situation. But then ask instead of being frustrated that you can't see it. It mentions 4 important things. Inovators. = brain+ Socio-economic benefits. = ROI x130 ~ 200.000 pund profit. Patients. = Nearly 50% improvement with Ayla Fast Implementation.= Greater likelihood of break even. So you can experience the post as you wish, but to claim that it is not relevant and has no justification is incorrect. IP guidance for NHS – webinar for innovators 05. December 2025 • 13.30 - 14.30 Online Details As part of the launch of the new IP guidance, DHSC and NHSE are holding a series of webinars aimed at helping the system gain a deeper understanding of the guidance and its objectives, as well as providing an opportunity for questions and answers. This webinar is tailored for innovators. Target audience: Clinical and non-clinical innovators currently working in NHS, innovators who wish or are interested in getting their innovations into NHS, and patient entrepreneurs Content: An introduction to intellectual property rights as described in the new guidance A review of the guidance: what it looks like, who it applies to, and the principles of good practice What the guidance means for innovators Case studies from innovators sharing real-world examples of navigating IP management within NHS in connection with their innovations. Register Microsoft Privacy Policy. This event is run by Microsoft Teams under the meeting organizer's leadership. The data processing that takes place in connection with this event is subject to the meeting organizer's terms.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
230 288
Myynti
Määrä
764 994
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 394 097 | - | - | ||
| 33 796 | - | - | ||
| 112 991 | - | - | ||
| 472 107 | - | - | ||
| 92 788 | - | - |
Ylin
0,011VWAP
Alin
0,01VaihtoMäärä
0 1 168 779
VWAP
Ylin
0,011Alin
0,01VaihtoMäärä
0 1 168 779
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 168 779 | 1 168 779 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 168 779 | 1 168 779 | 0 | 0 |